Drug Discovery & Pharmaceuticals

RSS

Phage engineering gives antibacterial therapy a new lease of life

Researchers have been identifying and modifying known phages to fight against infectious bacteria.

4 Oct 2019

Lonza and Nephron to present results of MODA-ES Platform implementation at 2019 ISPE Meeting & Expo

During the 2019 ISPE Meeting & Expo (27–30 October, Las Vegas, Nevada), Lonza and Nephron Pharmaceuticals Corporation will co-present the results of the first implementation of Lonza’s MODA-ES Platform, a next-generation electronic batch record solution for the pharmaceutical manufacturing industry.

From Lonza 4 Oct 2019

Kibow Biotech celebrates 22nd anniversary with plans to expand its product portfolio

Kibow® Biotech Inc, a pioneering probiotic company in gut modulation with its novel "Enteric Dialysis®" technology platform, is celebrating its 22-year anniversary on October 1st, 2019.

From Kibow Biotech Inc. 4 Oct 2019

Novel viral vector improves gene therapy for sickle cell disease

Researchers at the National Institutes of Health (NIH) have developed a unique, improved lentiviral vector for use in gene therapy for sickle cell disease.

3 Oct 2019

UCR biochemist receives grant to develop novel lead compound to treat breast cancer

A biochemist at the University of California, Riverside, has received a grant from the Congressionally Directed Medical Research Programs, or CDMRP, of the U.S. Department of Defense to develop a novel lead compound to treat breast cancer, the second most commonly diagnosed cancer among American women.

3 Oct 2019

New study shows link between antidepressant use and gestational diabetes mellitus

A study has found a link between the use of antidepressants and the development of gestational diabetes mellitus (GDM) in pregnant women.

2 Oct 2019

Using cloning technology to prevent esophageal cancer

Researchers at the University of Houston have replicated the genetic mechanism underlying the transformation of benign esophageal cells into a malignant tumor.

2 Oct 2019

New study shows response to HIV vaccine in 6 weeks

A US study on DNA-based and protein HIV vaccines has shown that an antibody and cellular immune response occurs within six weeks.

2 Oct 2019

Using AI to transform drug discovery in a big way

According to the National Cancer Institute, approximately 38 percent of men and women will be diagnosed with cancer at some point in their lives.

1 Oct 2019

Chemicals used for pharmaceuticals could be made more sustainably by new catalysts

High value chemicals used to make pharmaceuticals could be made much cheaper and quicker thanks to a series of new catalysts made by scientists at the University of Warwick in collaboration with GoldenKeys High-Tech Co., Ltd. in China.

1 Oct 2019

US Government to fund development of a 'universal flu vaccine'

The US government is to provide up to 400 million USD in funding to develop a “universal” flu vaccination at Duke University over the next seven years.

1 Oct 2019

Cannabis: CBD vs THC causes lower psychiatric side-effects

A study has revealed how cannabidiol works against tetrahydrocannabinol to prevent psychiatric side effects.

1 Oct 2019

Horizon Discovery announces full commercial licensing of GS knockout CHO K1 cell line to Glenmark

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes.

From Revvity 30 Sep 2019

RNA Targeted Small Molecules: Finally Drug the “Undruggable” RNA

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to overcome unique discovery and development challenges associated with novel RNA targeted small molecule therapeutics and achieve their seemingly limitless potential.

From RNA-Targeted Drug Discovery Summit 30 Sep 2019